Suma Krishnan

Suma Krishnan (President, R&D) sold 25,000 shares for $7.7M via scheduled 10b5-1 plan on 2026-06-04

Suma Krishnan executed 11 separate sales totaling 25,000 shares for $7,702,825.22 on 2026-06-04 at a blended average price of $308.11, reducing his holdings from 1.40M to 1.38M shares (-1.8%). This transaction is governed by a pre-arranged 10b5-1 trading plan adopted on 2025-09-04, making it a scheduled execution rather than a discretionary trade. The sell occurred near KRYS's 52-week high of $319.48 (current price $301.00, down 5.8% from peak), and in the context of his same-ticker history at KRYS, prior sales in March 2026 showed modest 30-day returns (ranging -1.4% to +1.4%) but consistently positive 90-day outcomes (+10.8% to +14.0%). With KRYS trading at a 39.45 P/E and demonstrating strong fundamentals (annual revenue growth of +33.9%, latest quarter revenue of $116.4M and net income of $55.9M), the liquidation reflects execution of a pre-planned schedule rather than a signal about conviction in the company's trajectory.

President of R&D sold 25,000 shares at blended $263.21; stock now at $253.69, -13.1% from high

Krishnan Suma, President of R&D at Krystal Biotech, executed 10 separate sales totaling 25,000 shares for $6,580,270.42 on 2026-03-04, reducing holdings from 1,428,155 to 1,403,155 shares (-1.8%). The sales occurred at prices ranging from $257.32 to $266.42, with a blended average of $263.21, versus the current price of $253.69. The stock is currently -13.1% from its 52-week high of $291.93. At the same ticker, Suma's prior five trades (all sales on 2025-12-04) posted 90-day returns ranging from +19.5% to +23.7%; none were well-timed at the 90-day mark. His cross-ticker track record across 20 prior sales shows an average 90-day return of +21.8% with a 0.00% well-timed rate, indicating a consistent pattern of selling before price increases rather than declines. The company reports strong recent fundamentals: quarterly revenue of $97,800,000.00, net income of $79,365,000.00, annual revenue growth of +33.9%, and a P/E of 23.58.

KRYS President R&D Sells 50,000 Shares for $11.0M at $220.15; Retains 1.48M; Stock at 52-Week High

Krishnan Suma, President of R&D, executed 16 separate sales totaling 50,000 shares for $11,007,332.86 on 2025-12-04, reducing holdings by 3.3% to 1,478,056 shares while the stock trades at its 52-week high of $234.13. The sales were distributed across a narrow price band ($214.25–$222.38), with a blended average of $220.15, suggesting execution during a concentrated window rather than opportunistic exit at isolated peaks. Across his prior 5 trades at KRYS (all sells in July 2025), none were well-timed at the 90-day mark, with post-sale returns ranging from +0.2% to +25.4%—the insider sold into strength each time and the stock continued to rise. Against his cross-ticker track record of 20 prior sells averaging +11.8% 90-day returns with only a 25.00% well-timed rate, this large sale at a 52-week high and current near-record valuation (P/E 34.13) occurs in a context of exceptional 90-day price momentum (+55.8%) and exceptionally strong fundamentals (net income $79.4M on $97.8M quarterly revenue, +473% annual revenue growth).

KRYS President of R&D Suma sells 35,873 shares (9 transactions) for $5,395,000.82 via blended avg $150.39 on 2025-07-14/15/16

Krishnan Suma, President of R&D at Krystal Biotech, executed 9 separate sales totaling 35,873 shares for $5,395,000.82 across three consecutive trading days (July 14–16, 2025), reducing his holdings by 2.3% to 1,508,056 shares. The blended average sale price of $150.39 lies 29.8% below the 52-week high of $213.66 but represents a gain relative to the current price of $150.08. Notably, Suma conducted four prior open-market sales at KRYS on July 9–10 (outcomes not yet measurable), creating a pattern of sustained selling activity at the R&D leadership level within a concentrated time window. His cross-ticker track record shows a 71.43% well-timed rate on 20 prior sells across other holdings, though same-ticker measurement is still pending; the timing pattern and scale of this week's sales merit close observation given the company's strong fundamental position (473.0% annual revenue growth, $88.2M latest quarterly revenue, P/E of 34.98).

Suma (President, R&D) sells 14,127 shares at avg $150.27 for $2.1M; retains 1.53M shares; stock -30.6% from 52-week high.

Krishnan Suma, President of R&D, executed 6 separate sales totaling 14,127 shares for $2,122,834.96 on July 9–10, 2025, at a blended average price of $150.27. This represents a 0.9% reduction in his holdings (down to 1,525,929 shares), well below the level that would signal material conviction loss. However, context is noteworthy: the stock now trades at $148.17, only 1.4% below his sale prices—marking immediate underperformance relative to his execution window. More striking is Suma's track record at KRYS: his prior 5 sales in March 2025 delivered 90-day negative returns ranging from -20.6% to -21.9%, with a perfect 5 of 5 well-timed at the 90-day mark. Current stock dynamics show -10.2% over the past 90 days and +6.1% over 30 days, placing this newest sale in a recovery phase that differs materially from his March pattern. KRYS fundamentals remain robust (revenue $88.2M latest quarter, net income $35.7M, P/E 34.54, annual growth +473.0%), suggesting the sale is unlikely driven by operational concerns.

KRYS President of R&D Krishnan Suma sold 50,000 shares for $8.9M at blended average $177.79 on 2025-03-13

Krishnan Suma, President of R&D at Krystal Biotech, executed 10 separate sales totaling 50,000 shares for $8,889,524.57 on 2025-03-13, reducing his holdings from 1,583,056 to 1,533,056 shares (a 3.2% reduction). The transaction occurred at prices ranging from $175.83 to $179.57, with a blended average of $177.79, slightly above the current price of $177.37. The company shows strong recent momentum (+18.3% over 30 days) and robust fundamentals (annual revenue growth of +473.0%, net income of $27,180,000.00). Notably, across Suma's prior 5 sales at KRYS in December 2024, none were well-timed at the 90-day horizon—all resulted in positive average returns, meaning the stock rose after each sale. Given the substantial position retained (1,533,056 shares post-transaction), the timing relative to the company's strong growth trajectory and recent positive price momentum warrants observation.

President of R&D Krishnan Suma sells 50,000 shares across 17 transactions totaling $8.2M at blended $164.80

Krishnan Suma, President of R&D at Krystal Biotech, executed 17 separate sales on 2024-12-13 totaling 50,000 shares (50.0K shares) for $8,240,023.06 ($8.2M), reducing holdings from 1,587,262 to 1,537,262 shares (-3.2% vs pre-transaction holdings). The multi-tranche execution at prices ranging from $163.04 to $170.47 suggests deliberate liquidation across multiple price points. His prior trades at KRYS show a 5 of 5 well-timed sell pattern on 2024-09-12, with 90-day returns of -11.1%, -9.9%, -8.7%, -10.7%, and -11.4%, indicating a consistent track record of selling ahead of subsequent declines at this ticker. The current stock price of $163.64 is down 23.4% from the 52-week high of $213.66 and down 11.2% over the past 30 days, suggesting the insider is selling into a period of significant price weakness rather than peak valuations.

Krishnan Suma (Pres, R&D) sold 50,000 shares at avg $197.77 for $9.9M on 2024-09-12

Krishnan Suma executed 15 separate sales totaling 50,000 shares for $9,888,276.35 at blended average price $197.77, reducing his holdings from 1,612,262 to 1,562,262 shares (-3.1%). The sale occurred as the stock traded near 52-week highs (current $201.58, within 5.6% of $213.66 range peak) and follows strong near-term momentum (+7.0% 30-day, +13.4% 90-day). His prior five trades at KRYS (all on 2024-06-11) posted positive 90-day returns ranging from 5.2% to 9.4%, with 0 of 5 being well-timed sells (stock rose after each); his cross-ticker track record shows 20 prior sells with 20.00% well-timed rate and modest average post-sell returns (+11.4% 30-day, +5.2% 90-day). The company trades at a P/E of 54.63 on $70.3M quarterly revenue and $15.6M net income. Without visibility into scheduling (10b5-1 plan disclosure) or other context, the timing against elevated valuation multiples warrants monitoring.